NCT01468532View on ClinicalTrials.gov

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 20, 2017

Study Completion Date

July 20, 2017

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

docetaxel

Given IV

DRUG

pasireotide

Given IM

DRUG

prednisone

Given PO

Trial Locations (1)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT01468532 - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter